Figure legends
Figure 1. Study flow chart.
SCIT: subcutaneous immunotherapy; V0: patients at the first visit; V1: patients at 1-year follow up; VAS: visual analogue scale; dSS: daily symptom score; dMS: daily medication score; CSMS: combined symptom and medication scores; QoL: quality of life; SAS: self-rating anxiety scale; SDS: self-rating depression scale.
Figure 2. Clinical manifestations in patients with scheduled and delayed SCIT.
(A-E), Mean values with 25th and 75th percentiles are indicated by scale bar. ****P < 0.0001, ***P < 0.001, **P < 0.01, *P < 0.05.
SCIT: subcutaneous immunotherapy; VAS: visual analogue scale; dSS: daily symptom score; dMS: daily medication score; CSMS: combined symptom and medication scores; QoL: quality of life; V0: patients at the first visit; V1: patients at 1-year follow up.
Figure 3. Emotional evaluation of different diseases and SCIT among patients in this study.
(A-B), Compared SAS and SDS of delayed SCIT group at V1, to delayed SCIT group and V0, scheduled SCIT group at V0 and V1 in this study and different diseases. Mean values with SD are indicated by scale bar.
(C), Proportion of SDS in patients with scheduled or delayed scheduled or delayed at V0 and V1. Mean values with 25th and 75th percentiles are indicated by scale bar.
(D), Correlation of SDS with time interval in the delayed SCIT group at V0.
****P < 0.0001, ***P < 0.001, **P < 0.01, *P < 0.05.
SCIT: subcutaneous immunotherapy; SAS: self-rating anxiety scale; SDS: self-rating depression scale; COVID-19: coronavirus disease 2019; AR: allergic rhinitis; CRS: chronic rhinosinusitis; SD: standard deviation; RT:radiotherapy; V0: patients at the first visit; V1: patients at 1-year follow up.
Figure 4. Compared clinical manifestations and control to depressive symptoms.
(A-E), Compared VAS, dSS, dMS, CSMS, and QoL of SCIT patients in non-depressed group to depressed group at V0 and V1. Mean values with 25th and 75th percentiles are indicated by scale bar. ****P < 0.0001, ***P < 0.001, **P < 0.01, *P < 0.05.
(F), Compared clinical control of SCIT patients to depressive symptom at V0 and V1. Mean values with 25th and 75th percentiles are indicated by scale bar. ***P < 0.001, **P < 0.01, *P < 0.05.
SCIT: subcutaneous immunotherapy; VAS: visual analogue scale; dSS: daily symptom score; dMS: daily medication score; CSMS: combined symptom and medication scores; QoL: quality of life; SDS: self-rating depression scale; V0: patients at the first visit; V1: patients at 1-year follow up.